Puma Biotechnology Inc. buy ProvisionYield47
Start price
31.08.24
/
50%
€2.20
Target price
30.09.24
-
Performance (%)
7.54%
End price
01.10.24
€2.37
Summary
This prediction ended on 01.10.24 with a price of €2.37. With a performance of 7.54%, the BUY prediction by ProvisionYield47 for Puma Biotechnology Inc. closed with a slight gain. ProvisionYield47 has 50% into this predictionPuma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Puma Biotechnology Inc. | -0.700% | -0.700% |
| iShares Core DAX® | -1.471% | 1.895% |
| iShares Nasdaq 100 | -0.486% | 4.395% |
| iShares Nikkei 225® | -2.115% | 2.450% |
| iShares S&P 500 | 0.394% | 3.118% |
Comments by ProvisionYield47 for this prediction
In the thread Trading Puma Biotechnology Inc.
Die von ProvisionYield47 gewählte maximale Laufzeit wurde überschritten